Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule.

2.50
Hdl Handle:
http://hdl.handle.net/10541/95929
Title:
Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule.
Authors:
Martin, C; Lund, B; Anderson, Heather; Thatcher, Nick
Abstract:
This paper reviews the toxicity profile of gemcitabine, a novel anticancer drug. Gemcitabine has been administered using two different treatment schedules: once weekly or twice weekly for 3 weeks followed by a week of rest (one cycle). It was well tolerated and alopecia was not a problem. Toxicity was greater in the twice-weekly schedule. Comparing the once-weekly with the twice-weekly schedule, WHO grade 3 or 4 thrombocytopenia was reported in 4.7 and 25.6% of patients, respectively. Other hematological toxicity was minimal. Transient WHO grade 3 or 4 elevations of ALT and AST occurred in 9.2 and 7.2% of patients, respectively, in the once-weekly schedule. For the twice-weekly schedule the corresponding percentages were 12.2 and 13.8%. Symptomatic toxicity was greater in patients who received twice-weekly gemcitabine. Nausea and vomiting was mild and generally well controlled without 5HT3 antagonists. However, there was a greater incidence of nausea and vomiting on the twice-weekly schedule. Flu-like symptoms were documented in 19.8% of patients receiving once-weekly and 63.3% of patients receiving twice-weekly gemcitabine. Peripheral edema, not related to cardiac, hepatic or renal failure, was seen more often in patients on twice-weekly treatment. As the efficacy of gemcitabine in non-small cell lung cancer was equivalent when using both regimens, the better tolerated and more easily administered once-weekly schedule is recommended.
Affiliation:
Lilly Research Centre, Windlesham, Surrey, UK.
Citation:
Gemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. 1996, 7 (3):351-7 Anticancer Drugs
Journal:
Anti-Cancer Drugs
Issue Date:
May-1996
URI:
http://hdl.handle.net/10541/95929
PubMed ID:
8792011
Type:
Article
Language:
en
ISSN:
0959-4973
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorMartin, Cen
dc.contributor.authorLund, Ben
dc.contributor.authorAnderson, Heatheren
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-04-07T16:19:54Z-
dc.date.available2010-04-07T16:19:54Z-
dc.date.issued1996-05-
dc.identifier.citationGemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule. 1996, 7 (3):351-7 Anticancer Drugsen
dc.identifier.issn0959-4973-
dc.identifier.pmid8792011-
dc.identifier.urihttp://hdl.handle.net/10541/95929-
dc.description.abstractThis paper reviews the toxicity profile of gemcitabine, a novel anticancer drug. Gemcitabine has been administered using two different treatment schedules: once weekly or twice weekly for 3 weeks followed by a week of rest (one cycle). It was well tolerated and alopecia was not a problem. Toxicity was greater in the twice-weekly schedule. Comparing the once-weekly with the twice-weekly schedule, WHO grade 3 or 4 thrombocytopenia was reported in 4.7 and 25.6% of patients, respectively. Other hematological toxicity was minimal. Transient WHO grade 3 or 4 elevations of ALT and AST occurred in 9.2 and 7.2% of patients, respectively, in the once-weekly schedule. For the twice-weekly schedule the corresponding percentages were 12.2 and 13.8%. Symptomatic toxicity was greater in patients who received twice-weekly gemcitabine. Nausea and vomiting was mild and generally well controlled without 5HT3 antagonists. However, there was a greater incidence of nausea and vomiting on the twice-weekly schedule. Flu-like symptoms were documented in 19.8% of patients receiving once-weekly and 63.3% of patients receiving twice-weekly gemcitabine. Peripheral edema, not related to cardiac, hepatic or renal failure, was seen more often in patients on twice-weekly treatment. As the efficacy of gemcitabine in non-small cell lung cancer was equivalent when using both regimens, the better tolerated and more easily administered once-weekly schedule is recommended.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntimetabolites, Antineoplastic-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshDeoxycytidine-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshDrug-Induced Liver Injury-
dc.subject.meshHumans-
dc.subject.meshKidney Diseases-
dc.subject.meshLung Neoplasms-
dc.subject.meshNeoplasms-
dc.subject.meshThrombocytopenia-
dc.titleGemcitabine: once-weekly schedule active and better tolerated than twice-weekly schedule.en
dc.typeArticleen
dc.contributor.departmentLilly Research Centre, Windlesham, Surrey, UK.en
dc.identifier.journalAnti-Cancer Drugsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.